

Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table SI. Baseline characteristics – estimates from EU, US, and pooled Cal/BD cream trials

Variable	EU	US	Pooled
Cal/BD cream arms	N = 213	N = 342	N = 555
Age, years (SD)	48.60 (13.70)	52.00 (14.40)	50.61 (14.14)
Sex, % male	63.85	59.36	61.09
Mean BSA, % (SD)	7.80 (6.50)	7.30 (6.00)	7.47 (6.20)
Mean mPASI (SD)	8.00 (3.9)	7.30 (3.90)	7.57 (3.90)
IGA			
Mild	17.84	19.88	19.08
Moderate	82.16	80.12	80.92
Skin type, %			
I or II	51.64	31.29	38.90
III	36.15	30.41	32.58
IV, V or VI	12.21	38.30	28.52
Cal/BD gel arms	N = 209	N = 337	N = 546
Age, years (SD)	51.50 (14.80)	52.60 (13.70)	52.22 (14.13)
Sex, % male	54.07	65.58	61.24
Mean BSA, % (SD)	7.80 (6.50)	8.40 (7.00)	8.15 (6.81)
Mean mPASI (SD)	8.00 (3.90)	7.70 (4.10)	7.82 (4.02)
IGA			
Mild	18.18	16.91	17.39
Moderate	81.82	83.09	82.61
Skin type, %			
I or II	50.24	32.34	39.04
III	36.36	33.23	34.42
IV, V or VI	13.40	34.42	26.54

BD, betamethasone dipropionate; BSA, body surface area; Cal, calcipotriol; IGA, Investigator's Global Assessment; MAIC, matching-adjusted indirect comparison; mPASI, modified Psoriasis Area and Severity Index; N_{eff} , effective sample size; SD, standard deviation.

Table SII. Baseline characteristics before and after matching – PSO-ABLE vs Cal/BD cream trials (anchored and unanchored MAICs).

Variable	Cal/BD cream (Pooled)	Cal/BD foam (PSO-ABLE)	
	Baseline Characteristics	Unweighted	Weighted
Cal/BD foam vs cream	N = 555	N = 162	N _{eff} = 128.57
% (N _{eff} /N) of original sample size	–	–	79.36 (128.57/162)
Age, years (SD)	50.61 (14.14)	54.46 (14.87)	50.61 (15.13)
Sex, % male	61.09	68.52	61.09
Mean BSA, % (SD)	7.47 (6.20)	6.49 (4.91)	7.47 (5.64)
Mean mPASI (SD)	7.57 (3.90)	6.54 (3.92)	7.57 (4.59)
IGA			
Mild	19.08	32.72	19.08
Moderate	80.92	67.28	80.92
Skin type, %			
I or II	38.90	28.40	38.90
III	32.58	40.74	32.58
IV, V or VI	28.52	30.86	28.52
Cal/BD gel arms	N = 546	N = 169	N _{eff} = 121.05
% (N _{eff} /N) of original sample size	–	–	71.63 (121.05/169)
Age, years (SD)	52.22 (14.13)	54.25 (14.75)	52.22 (14.54)
Sex, % male	61.24	58.58	61.24
Mean BSA, % (SD)	8.15 (6.81)	6.53 (4.95)	8.15 (5.79)
Mean mPASI (SD)	7.82 (4.02)	6.17 (3.11)	7.82 (3.98)
IGA			
Mild	17.39	26.63	17.39
Moderate	82.61	73.37	82.61
Skin type, %			

I or II	39.04	30.77	39.04
III	34.42	42.6	34.42
IV, V or VI	26.54	26.63	26.54

BD, betamethasone dipropionate; BSA, body surface area; Cal, calcipotriol; IGA, Investigator’s Global Assessment; MAIC, matching-adjusted indirect comparison; mPASI, modified Psoriasis Area and Severity Index; N_{eff} , effective sample size; SD, standard deviation.

Table SIII. Baseline characteristics before and after matching – Cal/BD foam vs Cal/BD cream trials (unanchored MAIC).

Variable	Cal/BD cream (Pooled)	Cal/BD foam (LEO90100-07)		Cal/BD foam (LP0053-1001)	
	Baseline Characteristics	Unweighted	Weighted	Unweighted	Weighted
Cal/BD foam vs cream	N = 555	N = 88	$N_{\text{eff}} = 71.97$	N = 294	$N_{\text{eff}} = 264.55$
% (N_{eff}/N) of original sample	–	–	81.78 (71.97/88)	–	89.98 (264.55/294)
Age, years (SD)	50.61 (14.14)	47.13 (14.18)	50.61 (13.5)	51.02 (13.89)	50.61 (14.05)
Sex, % male	61.09	53.41	61.09	62.59	61.09
Mean BSA, % (SD)	7.47 (6.20)	6.75 (5.03)	7.47 (5.7)	7.15 (6.16)	7.47 (6.43)
Mean mPASI (SD)	7.57 (3.90)	7.83 (4.65)	7.57 (4.32)	6.94 (4.09)	7.57 (5.00)
IGA					
Mild	19.08	12.50	19.08	17.01	19.08
Moderate	80.92	87.50	80.92	82.99	80.92
Skin type, %					
I or II	38.90	31.82	38.90	30.61	38.90
III	32.58	38.64	32.58	28.57	32.58
IV, V or VI	28.52	29.55	28.52	40.82	28.52

BD, betamethasone dipropionate; BSA, body surface area; Cal, calcipotriol; IGA, Investigator’s Global Assessment; MAIC, matching-adjusted indirect comparison; mPASI, modified Psoriasis Area and Severity Index; N_{eff} , effective sample size; SD, standard deviation.

Table SIV. Baseline characteristics before and after matching – PSO-LONG open-label phase vs Cal/BD cream trials (unanchored MAIC).

Variable	Cal/BD cream (Pooled)	Cal/BD foam (PSO-LONG)	
	Baseline Characteristics	Unweighted	Weighted
Cal/BD foam vs cream	N = 555	N = 586	N _{eff} = 548.48
% (N _{eff} /N) of original sample size	–	–	93.60 (548.48/586)
Age, years (SD)	50.61 (14.14)	52.27 (14.3)	50.55 (14.41)
Sex, % male	61.09	63.99	60.94
Mean BSA, % (SD)	7.47 (6.20)	7.89 (5.93)	7.45 (5.57)
Mean mPASI (SD)	7.57 (3.90)	7.42 (3.73)	7.55 (3.99)
IGA			
Mild	19.08	13.82	19.08
Moderate	80.92	86.18	80.76
Skin type, %			
I or II	38.90	39.25	38.75
III	32.58	31.91	32.58
IV, V or VI	28.52	28.84	28.52

BD, betamethasone dipropionate; BSA, body surface area; Cal, calcipotriol; IGA, Investigator’s Global Assessment; MAIC, matching-adjusted indirect comparison; mPASI, modified Psoriasis Area and Severity Index; N_{eff}, effective sample size; SD, standard deviation.

Table SV. Baseline characteristics before and after matching – Pooled Cal/BD foam treatment groups vs Cal/BD cream trials (unanchored MAIC).

Variable	Cal/BD cream (Pooled)	Cal/BD foam (Pooled treatment groups)	
	Baseline Characteristics	Unweighted	Weighted
Cal/BD foam vs cream	N = 555	N = 1130	N _{eff} = 1089.3
% (N _{eff} /N) of original sample size	–	–	96.40 (1089.3/1130)
Age, years (SD)	50.61 (14.14)	51.86 (14.36)	50.57 (14.47)
Sex, % male	61.09	63.45	60.99
Mean BSA, % (SD)	7.47 (6.20)	7.41 (5.81)	7.46 (5.80)
Mean mPASI (SD)	7.57 (3.90)	7.2 (3.95)	7.56 (4.43)
IGA			
Mild	19.08	17.26	19.08
Moderate	80.92	82.74	80.82
Skin type, %			
I or II	38.90	34.87	38.80
III	32.58	32.83	32.58
IV, V or VI	28.52	32.30	28.52

Pooled Cal/BD foam treatment groups: PSO-ABLE RCT arm, LP0053-1001 RCT arm, LEO90100-07 RCT arm, PSO-LONG open-label phase.

BD, betamethasone dipropionate; BSA, body surface area; Cal, calcipotriol; IGA, Investigator's Global Assessment; MAIC, matching-adjusted indirect comparison; mPASI, modified Psoriasis Area and Severity Index; N_{eff}, effective sample size; RCT, randomized controlled trial; SD, standard deviation.